Matches in SemOpenAlex for { <https://semopenalex.org/work/W2264572687> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2264572687 endingPage "18111" @default.
- W2264572687 startingPage "18111" @default.
- W2264572687 abstract "18111 Background: Amrubicin, a totally synthetic anthracycline, is a topoisomerase II inhibitor and highly effective for non-small cell lung cancer (NSCLC) as a single agent with response rates of 25% to 28%. We previously conducted a phase I trial of combination chemotherapy with irinotecan and amrubicin for NSCLC and found acceptable toxicity profiles with a favorable efficacy in patients with pretreated NSCLC. The aim of this phase II trial was to further evaluate its efficacy and toxicity in this population. Methods: Primary endpoint was objective response. Patients with NSCLC previously treated with one or two chemotherapy regimens were enrolled in this trial. Irinotecan and amrubicin were both administered on days 1 and 8, every 3 weeks at doses of 100 and 40 mg/m 2 , respectively. Response and toxicity were assessed according to the RECIST guideline and NCI Common Terminology Criteria for Adverse Events v3.0. Results: Thirty-one pretreated NSCLC patients were enrolled between 2004 and 2006. A median number of courses administered was 3 (range: 1 to 6). All patients and courses were assessable for efficacy and safety. Demographics of the patients were as follows: M/F: 21/10, Ad/others: 21/10, ECOG-PS 0/1: 12/19, and smoker/non-smoker: 21/10. Platinum-based regimens were commonly used as the prior chemotherapy. Objective response was obtained in 9 of the 31 patients with a response rate of 29.0% (95%CI: 12.1–46.0%). Grade 4 leukopenia and neutropenia were observed in 6 (19%) and 14 (45%) patients, respectively, whereas thrombocytopenia were generally mild. Grade 3 febrile neutropenia was observed in 7 patients (23%), of whom two patients further developed Grade 4 and 5 septic shock each. Other grade 3 or greater non-hematological toxicities included diarrhea, vomiting, pneumonitis, liver dysfunction in 4, 1, 1 and 2 patients, respectively. At the time of this analysis with a median follow-up time in the surviving patients of 7.5 months, median survival time and median progression-free survival time were 11.9 and 4.0 months, respectively. Conclusion: This combination seemed highly effective for pretreated NSCLC despite the moderate toxicity profiles. Development of efficient patient selection is needed to avoid the serious toxicities. No significant financial relationships to disclose." @default.
- W2264572687 created "2016-06-24" @default.
- W2264572687 creator A5000588868 @default.
- W2264572687 creator A5001897650 @default.
- W2264572687 creator A5006348007 @default.
- W2264572687 creator A5007888883 @default.
- W2264572687 creator A5039723911 @default.
- W2264572687 creator A5042110139 @default.
- W2264572687 creator A5047834232 @default.
- W2264572687 creator A5062920555 @default.
- W2264572687 creator A5066700160 @default.
- W2264572687 creator A5081173458 @default.
- W2264572687 date "2007-06-20" @default.
- W2264572687 modified "2023-09-25" @default.
- W2264572687 title "A phase II trial of combination chemotherapy with irinotecan and amrubicin in pretreated patients with non-small cell lung cancer" @default.
- W2264572687 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.18111" @default.
- W2264572687 hasPublicationYear "2007" @default.
- W2264572687 type Work @default.
- W2264572687 sameAs 2264572687 @default.
- W2264572687 citedByCount "0" @default.
- W2264572687 crossrefType "journal-article" @default.
- W2264572687 hasAuthorship W2264572687A5000588868 @default.
- W2264572687 hasAuthorship W2264572687A5001897650 @default.
- W2264572687 hasAuthorship W2264572687A5006348007 @default.
- W2264572687 hasAuthorship W2264572687A5007888883 @default.
- W2264572687 hasAuthorship W2264572687A5039723911 @default.
- W2264572687 hasAuthorship W2264572687A5042110139 @default.
- W2264572687 hasAuthorship W2264572687A5047834232 @default.
- W2264572687 hasAuthorship W2264572687A5062920555 @default.
- W2264572687 hasAuthorship W2264572687A5066700160 @default.
- W2264572687 hasAuthorship W2264572687A5081173458 @default.
- W2264572687 hasConcept C121608353 @default.
- W2264572687 hasConcept C126322002 @default.
- W2264572687 hasConcept C143998085 @default.
- W2264572687 hasConcept C197934379 @default.
- W2264572687 hasConcept C2776256026 @default.
- W2264572687 hasConcept C2776694085 @default.
- W2264572687 hasConcept C2777063308 @default.
- W2264572687 hasConcept C2777793932 @default.
- W2264572687 hasConcept C2778850193 @default.
- W2264572687 hasConcept C2779984678 @default.
- W2264572687 hasConcept C2780259306 @default.
- W2264572687 hasConcept C2908647359 @default.
- W2264572687 hasConcept C31760486 @default.
- W2264572687 hasConcept C526805850 @default.
- W2264572687 hasConcept C71924100 @default.
- W2264572687 hasConcept C99454951 @default.
- W2264572687 hasConceptScore W2264572687C121608353 @default.
- W2264572687 hasConceptScore W2264572687C126322002 @default.
- W2264572687 hasConceptScore W2264572687C143998085 @default.
- W2264572687 hasConceptScore W2264572687C197934379 @default.
- W2264572687 hasConceptScore W2264572687C2776256026 @default.
- W2264572687 hasConceptScore W2264572687C2776694085 @default.
- W2264572687 hasConceptScore W2264572687C2777063308 @default.
- W2264572687 hasConceptScore W2264572687C2777793932 @default.
- W2264572687 hasConceptScore W2264572687C2778850193 @default.
- W2264572687 hasConceptScore W2264572687C2779984678 @default.
- W2264572687 hasConceptScore W2264572687C2780259306 @default.
- W2264572687 hasConceptScore W2264572687C2908647359 @default.
- W2264572687 hasConceptScore W2264572687C31760486 @default.
- W2264572687 hasConceptScore W2264572687C526805850 @default.
- W2264572687 hasConceptScore W2264572687C71924100 @default.
- W2264572687 hasConceptScore W2264572687C99454951 @default.
- W2264572687 hasIssue "18_suppl" @default.
- W2264572687 hasLocation W22645726871 @default.
- W2264572687 hasOpenAccess W2264572687 @default.
- W2264572687 hasPrimaryLocation W22645726871 @default.
- W2264572687 hasRelatedWork W141948796 @default.
- W2264572687 hasRelatedWork W1833952634 @default.
- W2264572687 hasRelatedWork W1974759882 @default.
- W2264572687 hasRelatedWork W2046553998 @default.
- W2264572687 hasRelatedWork W2065287589 @default.
- W2264572687 hasRelatedWork W2118665425 @default.
- W2264572687 hasRelatedWork W2443672351 @default.
- W2264572687 hasRelatedWork W2590444302 @default.
- W2264572687 hasRelatedWork W3048392567 @default.
- W2264572687 hasRelatedWork W58191675 @default.
- W2264572687 hasVolume "25" @default.
- W2264572687 isParatext "false" @default.
- W2264572687 isRetracted "false" @default.
- W2264572687 magId "2264572687" @default.
- W2264572687 workType "article" @default.